IP Library › Granted Patent US 11,649,469
Granted Patent B2
US 11,649,469 · App. 16/411,793 · Granted May 16, 2023

Orthogonal Cas9 proteins for RNA-guided gene regulation and editing

Inventors: George M. Church (Brookline, MA); Kevin M. Esvelt (Auburndale, MA); Prashant G. Mali (La Jolla, CA)
Assignee: President and Fellows of Harvard College
C12N15/907C07K2/00C12N9/22C12N15/11C12N15/113C12N15/85C12N2310/3519C12N2320/33C12N2320/50C12N2800/107C12N2800/40C12N2800/80C12N2810/10C12N2830/00C12N2830/34C12N2999/007C12Y301/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,649,469
App. No.
16/411,793
Granted
May 16, 2023
Kind
B2
Abstract

Methods of modulating expression of a target nucleic acid in a cell are provided including use of multiple orthogonal Cas9 proteins to simultaneously and independently regulate corresponding genes or simultaneously and independently edit corresponding genes.

Claims (17)

1. A method of altering two or more target nucleic acids in a cell comprising

introducing into the cell a first foreign nucleic acid encoding two or more guide RNAs complementary to the two or more target nucleic acids,

introducing into the cell a second foreign nucleic acid encoding two or more orthogonal RNA guided DNA binding proteins of a Type II CRISPR system,

wherein the two or more guide RNAs and the two or more orthogonal RNA guided DNA binding proteins of the Type II CRISPR system are expressed,

wherein two or more co-localization complexes form with each including a guide RNA and an orthogonal RNA guided DNA binding protein of the Type II CRISPR system and a target nucleic acid and wherein the orthogonal RNA guided DNA binding protein of the Type II CRISPR system cuts or nicks the target nucleic acid.

2. The method of claim 1 wherein the two or more orthogonal RNA guided DNA binding proteins of the Type II CRISPR system are nucleases.

3. The method of claim 1 wherein the two or more orthogonal RNA guided DNA binding proteins of the Type II CRISPR system are nickases.

4. The method of claim 1 wherein the two or more orthogonal RNA guided DNA binding proteins of the Type II CRISPR system comprise a nuclease or a nickase.

5. The method of claim 1 wherein the cell is a eukaryotic cell.

6. The method of claim 1 wherein the cell is a yeast cell, a plant cell or an animal cell.

7. The method of claim 1 wherein each guide RNA is between about 10 to about 500 nucleotides.

8. The method of claim 1 wherein each guide RNA is between about 20 to about 100 nucleotides.

9. The method of claim 1 wherein each guide RNA is between about 100 to about 500 nucleotides.

10. The method of claim 1 wherein each guide RNA is a crRNA fused to a tracrRNA.

11. The method of claim 1 wherein a target nucleic acid is genomic DNA, mitochondrial DNA, viral DNA, or exogenous DNA.

12. The method of claim 1 wherein a plurality of target nucleic acids is cut or nicked.

13. The method of claim 1 wherein each orthogonal RNA guided DNA binding protein of the Type II CRISPR system is an orthogonal Cas9 protein.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 4, 2019
From: CHURCH, GEORGE M.; ESVELT, KEVIN M.; MALI, PRASHANT
To: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Reel/Frame 050255/0275 →
Continuity (3)
Continuation 14903728
Provisional Application 61844844 · Jul 10, 2013
Related Publication 20190367948A1 · Dec 5, 2019
Cited By (6)
US 12,215,343 US 12,251,429 US 12,612,643 US 12,630,838 US 12,637,690 US 12,649,928